Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.

@article{Blum2007PhaseIS,
  title={Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.},
  author={Joanne L. Blum and Michael A. Savin and Gerald Edelman and John E Pippen and Nicholas J. Robert and Brian Vincent Geister and Robert L Kirby and Alicia A Clawson and Joyce O'Shaughnessy},
  journal={Clinical breast cancer},
  year={2007},
  volume={7 11},
  pages={850-6}
}
PURPOSE Nanoparticle albumin-bound paclitaxel, a solvent-free, albumin-bound paclitaxel, demonstrated antitumor activity in patients with taxane-naive metastatic breast cancer (MBC). We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 administered weekly) to determine the antitumor activity in patients with MBC whose disease progressed despite conventional taxane therapy. PATIENTS AND METHODS Women with MBC that was previously treated with taxanes were eligible for participation… CONTINUE READING